|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||78.78 - 78.78|
|52-week range||78.78 - 97.30|
|Beta (5Y monthly)||0.53|
|PE ratio (TTM)||18.20|
|Forward dividend & yield||3.22 (4.09%)|
|Ex-dividend date||04 Mar 2021|
|1y target est||N/A|
Focused medicines company delivering strong operational performanceBuilding depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint Confident to grow sales 4%+ CAGR through 2026*, driven by multi-billion dollar sales from Cosentyx®, Entresto®, Kesimpta®, Zolgensma®, Kisqali® and Leqvio®**Up to 20 new assets with >1-billion dollar sales potential, set to potentially be approved by 2026, to fuel further growth through 2030 and beyond Cosentyx met
Deciphera (DCPH) announces a corporate restructuring plan to prioritize development of vimseltinib and DCC-3116, streamline commercial operations and reduce workforce by almost 35%. Shares rise.
Deciphera's (DCPH) sole marketed drug, Qinlock, is approved for treating advanced gastrointestinal stromal tumors. The recent regulatory setback for Qinlock has hurt the stock.